161 related articles for article (PubMed ID: 38336701)
1. Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation.
Zhang Q; Li Y; Zhang Y; Deng Z; Ding Y
World J Surg Oncol; 2024 Feb; 22(1):50. PubMed ID: 38336701
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.
Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA
Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666
[TBL] [Abstract][Full Text] [Related]
3. Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy.
Jacob JM; Ferry EK; Gay LM; Elvin JA; Vergilio JA; Ramkissoon S; Severson E; Necchi A; Killian JK; Ali SM; Schrock AB; Liu NW; Chung J; Miller VA; Stephens PJ; Welsh A; Corona RJ; Ross JS; Bratslavsky G
J Urol; 2019 Mar; 201(3):541-548. PubMed ID: 30291913
[TBL] [Abstract][Full Text] [Related]
4. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden.
Necchi A; Spiess PE; Costa de Padua T; Li R; Grivas P; Huang RSP; Lin DI; Danziger N; Ross JS; Jacob JM; Sager RA; Basnet A; Li G; Graf RP; Pavlick DC; Bratslavsky G
JAMA Netw Open; 2023 Dec; 6(12):e2348002. PubMed ID: 38150257
[TBL] [Abstract][Full Text] [Related]
5. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
6. Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma.
Chahoud J; Gleber-Netto FO; McCormick BZ; Rao P; Lu X; Guo M; Morgan MB; Chu RA; Martinez-Ferrer M; Eterovic AK; Pickering CR; Pettaway CA
Clin Cancer Res; 2021 May; 27(9):2560-2570. PubMed ID: 33441293
[TBL] [Abstract][Full Text] [Related]
7. Sintilimab-Induced Diabetic Ketoacidosis in a Patient with Radiation and Multichemorefractory Penile Cancer: A Case Report and Literature Review.
Lv C; Wu C; Zhang Y; Li W; Wang X; Liang L
Curr Oncol; 2022 Oct; 29(11):7987-7993. PubMed ID: 36354692
[TBL] [Abstract][Full Text] [Related]
8. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
9. Colorectal leiomyosarcoma with
Hong L; Wang YN; Zhang X; Zhou X; Fan S; Xu M; Zhang S; Jiang D
J Gastrointest Oncol; 2022 Jun; 13(3):1499-1504. PubMed ID: 35837171
[TBL] [Abstract][Full Text] [Related]
10. BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report.
Chen Z; Wang K; Zhao L; Gong L
Front Oncol; 2023; 13():1190100. PubMed ID: 37260982
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus infection affects treatment outcomes and the immune microenvironment in patients with advanced penile squamous cell carcinoma receiving programmed cell death protein 1 inhibitor-based combination therapy.
Wei L; Li Z; Guo S; Ma H; Shi Y; An X; Huang K; Xiong L; Xue T; Zhang Z; Yao K; Luo J; Han H
Cancer; 2024 May; 130(9):1650-1662. PubMed ID: 38157276
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of Penile Squamous Cell Carcinoma: Molecular Update and Systematic Review.
Ribera-Cortada I; Guerrero-Pineda J; Trias I; Veloza L; Garcia A; Marimon L; Diaz-Mercedes S; Alamo JR; Rodrigo-Calvo MT; Vega N; López Del Campo R; Parra-Medina R; Ajami T; Martínez A; Reig O; Ribal MJ; Corral-Molina JM; Jares P; Ordi J; Rakislova N
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008677
[TBL] [Abstract][Full Text] [Related]
13. Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report.
Del Giglio A; da Costa Aguiar Alves B; Murad AM; Fonseca FLA
J Med Case Rep; 2023 Sep; 17(1):407. PubMed ID: 37743480
[TBL] [Abstract][Full Text] [Related]
14. Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report.
Wu C; Fan M; Hu Y
Anticancer Drugs; 2022 Jan; 33(1):e734-e737. PubMed ID: 34387603
[TBL] [Abstract][Full Text] [Related]
15. Preoperative plasma IGFBP2 is associated with nodal metastasis in patients with penile squamous cell carcinoma.
Hu X; Chen M; Liu W; Li Y; Fu J
Urol Oncol; 2019 Jul; 37(7):452-461. PubMed ID: 31053522
[TBL] [Abstract][Full Text] [Related]
16. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Domchek SM; Postel-Vinay S; Im SA; Park YH; Delord JP; Italiano A; Alexandre J; You B; Bastian S; Krebs MG; Wang D; Waqar SN; Lanasa M; Rhee J; Gao H; Rocher-Ros V; Jones EV; Gulati S; Coenen-Stass A; Kozarewa I; Lai Z; Angell HK; Opincar L; Herbolsheimer P; Kaufman B
Lancet Oncol; 2020 Sep; 21(9):1155-1164. PubMed ID: 32771088
[TBL] [Abstract][Full Text] [Related]
17. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab.
Chahoud J; Skelton WP; Spiess PE; Walko C; Dhillon J; Gage KL; Johnstone PAS; Jain RK
Front Oncol; 2020; 10():615298. PubMed ID: 33425770
[TBL] [Abstract][Full Text] [Related]
19. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
Park J; Kim SI; Jeong SY; Kim Y; Bookman MA; Kim JW; Kim BG; Lee JY
Gynecol Oncol; 2022 Apr; 165(1):97-104. PubMed ID: 35153073
[TBL] [Abstract][Full Text] [Related]
20. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
